Premium
O2‐08‐04: Is the Incremental Diagnostic Value of Amyloid‐Pet Affected by Information on Other Core Biomarkers?
Author(s) -
Festari Cristina,
Altomare Daniele,
Bocchetta Martina,
Muscio Cristina,
Padovani Alessandro,
Frisoni Giovanni B.,
Boccardi Marina,
Boccardi Marina
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.439
Subject(s) - work up , medicine , dementia , diagnostic test , disease , neuroimaging , amyloid (mycology) , radiology , pathology , oncology , pediatrics , psychiatry
ful, estimates of the underlying event rates. Figures 1-3 below are from theMayo Clinic Study of Aging (MCSA), a population based study of cognitive aging. Figure 1 shows the underlying multi-state model that was assumed. Figure 2 shows the estimated progression rates from the model as a function of age, and figure 3 the fitted model’s predicted distribution of states for living subjects. We see the following: (1) Rates increase exponentially with age, only one plateaus; (2) Simple biology (figure 2) can generate a complex interplay of observed frequency (figure 3); amd (3) Stage 1 NIA-AA pre-clinical AD (A+N-) is not benign. It carries an elevated risk for transition to A+N+ which in turn has the highest rate of transition to dementia. Conclusions: Multi-state models are a worthwhile addition to the analysis toolbox, and can give further insight into underlying disease processes. Computational tools to fit the models are increasingly available.